In setback for Lilly, FDA limits dosage, slaps warning on new arthritis drug
The Indianapolis-based drugmaker has been working for years to develop the much-anticipated drug, which some analysts had said might ring up $2 billion a year in sales.
Eli Lilly and Co.
Articles
Trump health secretary: Drugmakers must help cut prices, or else
Alex Azar, secretary of Health and Human Services and a former executive of Eli Lilly and Co., said Monday that the Trump administration plans to turn up the heat on uncooperative pharma firms.
Lilly shareholders reject proposals to lower takeover barriers
Failure to approve the proposals keeps Eli Lilly and Co.’s supermajority-vote requirement for takeovers and staggered board elections intact.
UPDATE: Eli Lilly buying immuno-oncology company for $1.6 billion
The Indianapolis-based pharmaceutical giant said it plans to acquire ARMO BioSciences Inc., which is working on treatments that activate the immune system of cancer patients to recognize and eradicate tumors.
Lilly rolls out its first-ever TV campaign for a cancer drug
The ads for the metastatic breast cancer drug Verzenio show women in their 50s and 60s looking resolute and indomitable, surrounded by smiling friends and family.
Major health initiative targets 3 Indianapolis neighborhoods with high diabetes rates
A five-year, $7 million program is led and supported by a coalition of local health institutions, including Eli Lilly and Co., Fairbanks School of Public Health and Eskenazi Health. It is based on a model that Lilly has used in other countries.
Eli Lilly’s next big push likely to come in pain treatments
The Indianapolis-based drugmaker has several pain medications in the pipeline, including potential treatments for migraine headaches, arthritis and chronic back pain.
Private equity firms mull bids for Eli Lilly’s Elanco unit
The Indianapolis pharmaceutical giant is evaluating whether to keep the division, which makes animal-health products, or sell it or take it public. An analyst said it might fetch $16 billion.
Eli Lilly hikes forecast after better-than-expected first quarter
Indianapolis-based Eli Lilly and Co. on Tuesday reported quarterly revenue and adjusted earnings that exceeded analyst forecasts.
Drug industry sets lobbying records as pricing pressure looms
The drug industry set several quarterly records for lobbying spending in the first three months of 2018, but Indianapolis-based Eli Lilly and Co. actually reduced lobbying expenditures.
Rare loss for Big Pharma will cost industry billions
Drugmakers will have to offer a much more generous discount to Medicare beneficiaries who fall into the so-called donut hole coverage gap.
Lilly signs licensing deal with biotech startup for diabetes drug
Under the agreement, Lilly will pay Sigilon Therapeutics up to $410 million if the technology hits certain milestones.
Former Lilly CFO Rice to lead CVS Caremark, report says
Derica Rice, 53, one of the nation’s most powerful black executives, retired from Indianapolis-based drugmaker Eli Lilly and Co. in December, after the company passed him over when naming a new CEO.
Lilly revives proposals that would lower takeover barriers
The company’s board is asking shareholders to support two corporate-governance proposals, including one that would eliminate a requirement that buyout bids garner at least 80 percent shareholder approval.
‘Rigged’ system blocks lower-cost drugs, head of FDA says
FDA Commissioner Scott Gottlieb aimed particular criticism at giant pharmacy benefit managers that contract with health plans to administer coverage of drugs, saying the industry’s tactics have stymied cheaper copies of expensive biotechnology drugs.
Ricks makes $14.4 million in first year as Eli Lilly CEO
Eli Lilly CEO David Ricks’ first year in charge was marked by a wave of activity, including a huge corporate restructuring. The company’s stock price climbed about 6.2 percent during the year.
FDA opens new path for Alzheimer’s therapy as failures mount
The Food and Drug Administration proposal will create new opportunities for drugmakers after repeated failures from companies including Indianapolis-based Eli Lilly and Co.
Hot-selling Lilly anti-inflammatory drug passes key hurdle for third use
The Indianapolis-based drugmaker said the medicine, called Taltz, proved effective for treating a type of back stiffness, and hopes to submit it for government approval this year.
Trump’s big promises on drug costs followed by modest steps
As a candidate, President Trump advocated Medicare negotiations and allowing consumers to import medicines from abroad. His current strategy recommends changes to policies that the administration believes unwittingly lead to higher prices, and suggests ways to speed drugs to market and increase competition.
Elanco uncertainty has Greenfield on edge
Since October, when Eli Lilly and Co. announced it was reviewing whether to sell or spin off Elanco, Greenfield city leaders have been wondering what the future holds for the city’s economy.